E
Ellen McErlean
Researcher at Cleveland Clinic
Publications - 36
Citations - 3004
Ellen McErlean is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Myocardial infarction & Evacetrapib. The author has an hindex of 16, co-authored 33 publications receiving 2594 citations. Previous affiliations of Ellen McErlean include Case Western Reserve University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Prognostic Value of Myeloperoxidase in Patients with Chest Pain
Marie Luise Brennan,Marc S. Penn,Frederick Van Lente,Vijay Nambi,Mehdi H. Shishehbor,Ronnier J. Aviles,Marlene Goormastic,Michael Pepoy,Ellen McErlean,Eric J. Topol,Steven E. Nissen,Stanley L. Hazen +11 more
TL;DR: Myeloperoxidase levels, in contrast to troponin T, creatine kinase MB isoform, and C-reactive protein levels, identified patients at risk for cardiac events in the absence of myocardial necrosis, highlighting its potential usefulness for risk stratification among patients who present with chest pain.
Journal ArticleDOI
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff,Stephen J. Nicholls,Jeffrey S. Riesmeyer,Philip J. Barter,H. Bryan Brewer,Keith A.A. Fox,C. Michael Gibson,Christopher B. Granger,Venu Menon,G. Montalescot,Daniel J. Rader,Alan R. Tall,Ellen McErlean,Kathy Wolski,Giacomo Ruotolo,Burkhard Vangerow,Govinda Weerakkody,Shaun G Goodman,Diego Conde,Darren K. McGuire,Jose C. Nicolau,Jose L. Leiva-Pons,Yves Pesant,Weimin Li,David Kandath,Simon Kouz,Naeem Tahirkheli,Denise Mason,Steven E. Nissen +28 more
TL;DR: Treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high‐risk vascular disease, and had favorable effects on established lipid biomarkers.
Journal ArticleDOI
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Stephen J. Nicholls,H. Bryan Brewer,John J.P. Kastelein,Kathryn A. Krueger,Ming Dauh Wang,Mingyuan Shao,Bo Hu,Ellen McErlean,Steven E. Nissen +8 more
TL;DR: Compared with placebo or statin monotherapy, evacetrapib as monotherapy or in combination with statins increased HDL-C levels and decreased LDL-C Levels, and the effects on cardiovascular outcomes require further investigation.
Journal ArticleDOI
Prognostic Value of Myeloperoxidase in Patients With Chest Pain
Marie Luise Brennan,Marc S. Penn,Frederick Van Lente,Vijay Nambi,Mehdi H. Shishenbor,Ronnier J. Aviles,Marlene Goormastic,Michael Pepoy,Ellen McErlean,Eric J. Topol,Steven E. Nissen,Stanley L. Hazen +11 more
TL;DR: Elevated plasma myeloperoxidase concentration appears to be a marker of vulnerable coronary artery plaque, and it helps to identify patients at risk for major adverse cardiac events independently of evidence that myocardial necrosis is present.
Journal ArticleDOI
Effects of a Potent and Selective PPAR-α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia: Two Randomized Controlled Trials
Steven E. Nissen,Stephen J. Nicholls,Kathy Wolski,Daniel C. Howey,Ellen McErlean,Ming Dauh Wang,Elisa Gomez,John M. Russo +7 more
TL;DR: In patients with dyslipidemia, LY518674 and fenofibrate decreased triglycerides and increased HDL-C but also increased serum creatinine but did not further reduce LDL-C in combination with atorvastatin.